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In this work a radiopaque premixed calcium phosphate cement (pCPC) has been developed and evaluated in vivo.R a d i o p a c i t y
was obtained by adding 0–40 % zirconia to the cement paste. The eﬀects of zirconia on setting time, strength and radiopacity
were evaluated. In the in vivo study a 2 by 3.5mm cylindrical defect in a rat vertebrae was ﬁlled with either the pCPC, PMMA or
bone chips. Nano-SPECTCT analysiswasused to monitorosteoblastactivity during bone regeneration. The study showed thatby
adding zirconia to the cement the setting time becomes longer and the compressive strength is reduced. All materials evaluated in
the in vivo study ﬁlled the bone defect and there was a strong osteoblast activity at the injury site. In spite ofthe osteoblast activity,
PMMAblocked bone healingandthe bone chips group showed minimalnew bone formation.At 12weeks the pCPC waspartially
resorbed and replaced by new bone with good bone ingrowth. The radiopaque pCPC may be considered to be used for minimal
invasive treatment of vertebral fractures since it has good handling, radiopacity and allows healing of cancellous bone in parallel
with the resorption of the cement.
1.Introduction
Due to an aging population together with a lifestyle that
requires less movement, many elderly today have weak bone
structure. One complication with a weaker bone structure
is an increased fracture risk, especially in the vertebras.
Vertebral compression fractures are painful. In order to
relief the pain the fracture can be stabilized using vertebro-
plasty [1]. Traditionally polymethylmethacrylate (PMMA)
cement has been used in this procedure. However there
are complications associated with the use of PMMA, such
as cement leakage and increased risk of adjacent fractures
[2, 3], so there is increased interest in ﬁnding alternative
materials. Calcium phosphate cements (CPCs), which were
ﬁrst presented in the beginning of the 80s [4, 5], are
alternatives to PMMA. Thanks to the chemical resemblance
to bone the CPCs have good biocompatibility and are
resorbed in vivo [6, 7]. CPCs consist of calcium phosphate
salts, which upon mixing with water dissolve and then
precipitate to form a solid body of either brushite or apatite
depending on the pH of the solution [4]. There are already
numerous commercial CPCs used in the clinical practice
as bone void ﬁllers [8]; however very few are intended for
use in vertebroplasty. There are two major obstacles for
the CPCs when to be used in spinal applications: handling
and radiopacity. To obtain a CPC with suﬃcient working
time, which can be injected through a G11 or G13 needle
without ﬁlter pressing, is not an easy task, and various
publications on injectability and setting regulators can be
found [9–13]. Recently an innovative approach was taken
wherewaterwasexchangedforglycerolasmixingliquid[14].
This gives the surgeon unlimited time for the injection, and
the viscosity remains constant until the premixed calcium
phosphate cement (pCPC) is in place and the cement comes
in contactwith water. The premixed concepthasbeen shown
to work on both brushite and apatite cements [14–16].2 International Journal of Biomaterials
During injection into the vertebra it is important to be able
to follow the cement with X-ray to avoid leakage. In the case
of PMMA this is solved by adding either ZrO2 or BaSO4
[17, 18]. A number of additives have been suggested to add
radiopacity to CPCs, such as bismuth [19] and strontium
[20]. However very little has been published describing CPC
with ZrO2 and BaSO4, which are well documented for use in
PMMA cements.
The aim of this paper is to evaluate a premixed calcium
phosphate cement containing ZrO2, regarding its setting
time, compressive strength, and radiopacity as well as its in
vivobehaviour in a vertebral rat model.
2.Methods
2.1. Eﬀects of ZrO2 Content
2.1.1. Cement Preparation. The powder part of the cement
consisted of β-tricalciumphosphate (β-TCP, Fluka), mono-
calcium phosphate monohydrate (MCPM, Scharlau), and
zirconia (ZrO2,Sigma-Aldrich). MCPM and β-TCP were
mixed in equimolar amounts. To this 0, 10, 20, 30, or 40%
(w/w) ZrO2 was added. The powder was then mixed with
glycerol(99%,Sigma-Aldrich).Inallevaluatedcompositions
the powder/liquid ratio was 4.2g/mL. Before mixing, the β-
TCP and ZrO2were sterilized using heat (200◦C during 2
hours [21]),and the MCPM wassterilized by soaking in 70%
ethanol for >24 hours.
2.1.2. Compressive Strength. After mixing, the paste was
injected into cylindrical moulds ∅ 6mm, height 12mm
open at both ends for compression strength testing and then
immersed in 37◦C phosphate buﬀered saline (PBS, pH 7.4,
Sigma-Aldrich) to simulate physiological pH and start the
setting reaction. After 24 hours the samples were removed
from the mould, and a universal testing machine (Shimadzu
AGS-H) was used with a cross-head speed of 1mm/min; the
maximum compressive stress was recorded for each sample.
A thin plastic ﬁlm was placed between the sample and the
crosshead in order to reduce the eﬀect of defects deriving
from the mould. Six samples were tested per group.
2.1.3. Setting Time. After mixing the cement paste was
injected into 4 cylindrical moulds ∅ 6mm, height 3mm for
setting time. To initiate the setting of the cement the moulds
were immersed in 37◦CP B S .T h ec e m e n tw a sc o n s i d e r e dt o
have set when the sample couldsupport the 453.5g Gillmore
needle with a tip diameter of 1.06mm without breaking.
The four samples were tested consecutively with a 4-minute
interval between each test. The mean between the time when
the sample supported the weight and the previous time
where the sample broke under the load was regarded as the
setting time.Three measurementswere made foreachgroup.
2.1.4. Radiopacity. For X-ray opacity measurements 1mm
thick samples were produced. The X-ray opacity was mea-
sured at 1mAs, with 40 and 80kV. A 1mm sample of a
PMMA-based cement (Vertebroplastic, DePuy, USA), which
h a sb a r i u ms u l p h a t ea sr a d i o p a c i ﬁ e r ,w a su s e da sc o n t r o l
alongwithanaluminiumwedge0.5–2.5mmin0.5mmsteps.
2.2. In Vivo. The cement used in the in vivo studies was
prepared as described above containing 20% ZrO2.1 m L
syringes were preﬁlled with the premixed cement under
aseptic conditions 4 days before the in vivo experiments. The
syringes were stored at 8◦Cu n t i ls u r g e r y .
2.2.1. Animal Surgery. Three-month old, 480–600g male
Wistar rats were anesthetized with halothane. The surgical
area was washed with betadine three times, and a ligature
was applied at the root of the tail to prevent bleeding. After
removing the distal part of the tail a 2.0mm diameter and
3.5mm deep hole was drilled axially into the 4th or 5th
tail vertebra. In order to stall the regeneration of bone a
stainless steel wire was implanted into the hole. The wound
was closed using a nonresorbable polypropylene suture.
The localization of the wire was veriﬁed by X-ray. Twelve
weeks later the animals were anesthetized again, and the
implanted wire was removed. The hole was ﬁlled either with
PMMA (Heraeus Palacos R) (n = 5), pCPC (n = 5), or
with impacted human lyophyilized bone chips (n = 5),
and the wound was closed. Bone regeneration was followed
with nano-SPECT/CT. Twelve weeks later the animals were
overanesthetized and sacriﬁced. The last two vertebrae (last
operatedvertebraplusonehealthyvertebra)wereﬁxedin4%
formaldehyde and analyzed with micro-CT and histology.
2.2.2. Nano-SPECT/CT Analysis. Single isotope nano-
SPECT/CT (Bioscan) imaging acquisitions were performed
on 2-3 rats from each group in order to follow the
integration of the bone substitutes and bone regeneration.
Nano-SPECT/CT was carried out weekly for 6 weeks and
once again on the 12th week. The rats were inoculated
with 0.5mL, 150MBq of 99mTc-methyl diphosphonate
(99mTc-MDP) through the tail vein under halothane
anesthesia. Metastable technetium (99mTc) is tagged onto a
phosphonate compound such as MDP to generate 99mTc-
MDP, which selectively concentrates in osteoblasts. The
selective accumulation of 99mTc-MDP is ensured by both
chemical adsorption onto the surface of the hydroxyapatite
in bone and incorporation into the crystalline structure
of hydroxyapatite [22]. Two hours later the animals were
anesthetized with euthasol intraperitoneally, and 30-minute
image acquisitions were performed. Regeneration activity
was expressed as a percentage compared to the proximal
healthy vertebra depending on isotope density.
2.2.3. Micro-CT Analysis. The operated vertebrae were ex-
amined with microtomography (Skyscan 1172 X-ray micro-
tomography Skyscan, Kontich, Belgium). Scans were carried
out applying a 60kV voltage and an Al-ﬁlter. Reconstruction
wasdonewith amodiﬁedFeldkampalgorithmusingSkyscan
Nrecon software. Microtomographical reconstruction was
obtained by rotating the view through 180 degrees (rotation
step 0.5 degrees). SkyScan CTvox (Kontich, Belgium) was
used for the 3D visualization.International Journal of Biomaterials 3
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Figure 1: Diagram showing the inﬂuence of ZrO2 content (0
to 40%) on compressive strength of the pCPC after 24 hours
incubation in PBS at 37◦C. Error bars represent standard deviation,
n = 6.
2.2.4. Histology. The formaldehyde-ﬁxed 4th and 5th verte-
brae were decalciﬁed by immersing the samples in Biodec-R
solution for 1 week. Five micron longitudinal sections were
cut from the paraﬃn blocks and mounted on glass slides.
Conventional hematoxylin-eosin (Merck & Co) staining was
used to conﬁrm the results of the micro-CT measurements.
3.Results
3.1. Evaluation of ZrO2 Content
3.1.1. Compressive Strength and Setting Time. The com-
pressive strength is reduced with an increasing content of
ZrO2 as seen in Figure 1. When there is no ZrO2 in the
cement the compressive strength is 13.5 (±0.6)MPa, and
with 40% ZrO2 the compressive strength is lowered to
8.0 (±1.2) MPa. Values in parenthesis are the standard
deviation. With 20% ZrO2 the strength is 11.8 (±1.2)MPa.
An increasing amount of ZrO2 also increased the setting
time as seen in Figure 2.0 %Z r O 2 gives a setting time of
20 (±4)min, 20% ZrO2 has a setting time of 26 (±2) and
the longest setting time was measured with 40% ZrO2,3 7
(±2)min.
3.1.2. Radiopacity. From the X-ray images in Figure 3 it
couldbeconcludedthat20%ZrO2 gaveasuﬃcientradiopac-
ity, comparable to 1–1.5mm aluminium and Vertebroplastic
at 40kV and 80kV. A good radio contrast was obtained in
vivo with the pCPC, which can be observed in the micro-CT
images in Figure 6.
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Figure 2: Diagram showing the inﬂuence of ZrO2 content (0 to
40%) on setting time of the pCPC. Error bars represent standard
deviation, n = 3.
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Figure 3: X-ray image comparing pCPC samples containing 0 to
40%ZrO2, with acommercialPMMA cement (Vertebroplastic) and
an aluminium wedge with 0.5 to 2.5mm in thickness. The X-ray
opacity was measured at 1mAs, with 40kV (a) and 80kV (b).4 International Journal of Biomaterials
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Figure 4: Comparison ofintensities from CT (blue line) and nano-
SPECT (red line) images. A representative image shows that the
peak intensity of a vertebral epiphysis can be localized on the basis
of the CT image and compared to the defect site. SPECT intensities
reﬂect osteoblast activity. The defect site has a signiﬁcantly higher
osteoblast activity than the normal bone.
3.2. In Vivo. The animals tolerated all the implants well,
there was no sign of wound infection or rejection.
3.2.1. Nano-SPECT/CT Analysis. The osteoblast activity was
monitored during 12 weeks after implantation (Figure 5).
The activity was calculated as the percentage of the next
healthyvertebra.TheCTgraph(bluelineinFigure 4)follows
the structure of the two vertebrae, while the pixel intensity
is much higher in the operated vertebra compared to the
healthy control vertebra when looking at the red line in
Figure 4. The same trend was observed in all animals. In all
three groups the values are higher than those of the normal
bone as seen in Figure 5. The osteoblast activity in this
cavitary defect is higher than the normal bone and remains
high during the ﬁrst 5 weeks after implantation. The overall
activity is comparable among the groups, with a slight trend
of pCPC for an even higher activity, especially at week 2,
while a slight decrease can be observed in the bone chips and
the PMMA groups. The osteoblast activity did not return to
normal levels (unit 100 in the graph) in any animals in any
group during the study.
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Figure 5: Diagram showing the osteoblast activity in the operated
vertebra compared to the adjacent vertebra. The lines represent the
mean value and the dots the individual animals value. The 12-week
nano-SPECT/CTfollowup showed the highest osteoblastactivity in
the pCPC group during the ﬁrst 5 weeks. Although the diﬀerences
between the three groups level oﬀ after the 5th week, pixel intensity
stays higher in all three groups compared to the neighbouring
healthy vertebra.
3.2.2. Micro-CT Analysis. In Figure 6 representative 3D
renderings of the ﬁlled defect along with cross-sections are
presented. As seen in the ﬁgure, in the vertebrae ﬁlled with
PMMA(upper),thedefectwascompletelyﬁlledwithPMMA
and no bone formation was observed. The PMMA was
demarcated from the bone. This result was consistent in all
animals in the PMMA group.
In the vertebrae ﬁlled with bone chips no or slow
resorption could be observed, and limited bone healing.
There was no bony connection between the bone chips and
the new bone as seen in the cross-section CT image in
Figure 6(bottom).Therewassomeboneformation;however
t h eb o n ec h i p sa r es t i l ld e m a rcated from the bone. In the
histology image in Figure 7(b) bone chips are seen to have
direct contact with newly formed bone.
In the case of pCPC in the vertebrae (middle image
in Figure 6) new bone formation can be observed (blue
arrow). The pCPC has been partially resorbed and replaced
with bone. However the ZrO2 present in the pCPC for
radiopacity is not resorbed, and thus residues of the cement
can be observedin the newly formed bone. Histologyresults,
(Figure 7(a)) conﬁrmed the nanoSPECT and CT results for
the pCPC. Direct contact with newly formed bone and no
immunologic reaction was observed.International Journal of Biomaterials 5
Figure 6: The representative micro-CT images after 12 weeks of
the operated vertebra. PMMA (upper image) is compacted in the
hole,butnoboneformationwasobserved;aradiolucentareaisseen
between the PMMA and the bone. The pCPC (middle image) is
slowly resorbed, and new bone is formed in connection with the
pCPC (arrow). There was some bone formation around the bone
chips, however considerable radiolucent areas can also be observed.
4.Discussion
The premixed cement presented here contains ZrO2 to
obtain radiopacity. An increasing amount of ZrO2 in the
cement pastes will decrease the amount of reactive material
(MCPM and β-TCP). When the cement comes in contact
with water the reactive material will dissolve and monetite
crystals start to form giving the paste its strength. Accord-
ingly the compressive strength was reduced from 13.5 (±0.6)
to 8.0 (±1.2)MPa with an increase of ZrO2 from 0 to 40%
ZrO2 (Figure 1). In relation to this the setting time increased
with an increasing amount of ZrO2.0 %Z r O 2 gave a setting
time of 20 (±4) minutes compared to 37 (±2) minutes with
40% ZrO2 (Figure 2) .T h es a m et r e n dw a ss e e ni nap r e v i o u s
publication on premixed monetite cement [16] where high
strength samples also showed shorter setting time. Since
the method used for testing the setting time measures how
fast the cement obtains a certain strength this relation is
expected. As the ZrO2 content increases it was noted during
the experiments that the viscosity of the cement decreases.
Since the ZrO2 has higher density than the β-TCP and
(a) (b)
Figure 7: Histological signs of remodelling. Hematoxyline-Eosine
stained sections. (Magniﬁcation:40x). (a) showsthe injected pCPC
in contact with newly formed bone. (b) shows an implanted
bone chip. Newly formed bone is seen in contact with the slowly
remodelling calciﬁed bone fragment.
MCPM more ZrO2 implies that the total powder volume
will be smaller when using the same weight of powder. With
less powder volume the glycerol will more easily encase the
powder particles thus reducing the viscosity. With 20% ZrO2
thecompressivestrengthwas11.8(±1.2)MPaandthesetting
time 26(±2)minutes, which are acceptablevaluesforcertain
vertebral fractures, and this also gave a good radiopacity.
Therefore thisformulation waschosen forthein vivo studies.
As seen in the results from the nano-SPECT (Figure 5)
theosteoblastactivityinthiscavitarydefectishigherthanthe
normal bone and remains high during the 12-week duration
of the study. This indicates that bone formation was ongoing
throughout the study. Although there were too few animals
in the study to do statistical analysis on the results from
the nano-SPECT a slight trend could be observed indicating
that the pCPC has a positive eﬀect on the osteoblast activity
compared to the other groups. It is most clear in weeks 2, 3,
and 4. The monetite formed when pCPC sets is chemically
less stable than apatite under in vivo conditions where the
pH is ∼7.4, thus it can be resorbed faster, than, for example,
apatite forming CPCs and bone grafts [23]. When the pCPC
is resorbed, calcium and phosphate ions are released which
stimulate the osteoblasts [24]. This could explain why the
osteoblast activity seems to be slightly higher in the pCPC
animals.
Looking at the CT results the PMMA group present
no surprises. The PMMA ﬁlls the defect, and it cannot be
resorbed, thus any new bone formation into the cavity is
blocked. The results from the bone chips on the other hand
show new bone formation into the cavity; however the bone
chips do not show signs of bony reconsolidation, and it is
clearly demarcated from the host bone. This is probably due
to the highly compacted structure of the bone chips, so their
osteoinductive potential can only be seen on the contact
surface, and penetration of the graft by the host tissue is
limited.6 International Journal of Biomaterials
In the pCPC group new bone formation was observed
and there is connection between the new bone and the
material. This indicates that the pCPC has osteoconductive
properties, which has been shown for monetite in previous
publications[25, 26]. The resorption of pCPC and new bone
formation, that is, the remodelling, seems to be in balance in
thismodel. The ZrO2 is not resorbed; however theCT results
indicate that good bone integration was achieved around the
ZrO2. Previous studies where ZrO2 was used in contact with
bone also report good bone-implant contact [27]. In future
studies the bone integration of ZrO2 will be evaluated more
thoroughly.
5.Conclusions
The premixed calcium phosphate cement containing 20%
ZrO2 wasfoundtohaveexcellenthandling,goodradiopacity,
and suﬃcient strength and setting time.
All materials evaluated in the study ﬁlled the bone cavity,
and in each case there was a strong osteoblast activity at
the injury site. However, in spite of the osteoblast activity,
PMMAblockedbonehealing,andevenbonechipsseemedto
beless eﬀectivethanpCPC.The pCPC was partially resorbed
a n dr e p l a c e db yn e wb o n e .
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